On 6 February, GlaxoSmithKline (GSK) shared interim analysis data from its Phase III DREAMM-7 trial evaluating the combination of antibody-drug conjugate Blenrep (belantamab mafodotin) with Takeda’s Velcade (bortezomib) and dexamethasone (BorDex) versus J&J’s Darzalex (daratumumab) and BorDex for relapsed or refractory multiple myeloma (MM) for patients who received at least one previous line of therapy. At a median follow-up of 28.2 months, patients in the Blenrep arm experienced 36.3 months of median progression-free survival (PFS) the trial’s primary endpoint, a significant improvement from the 13.4 months in the comparator arm. The company also reported a 43% reduction in risk of death compared to BorDex. Typically patients in the frontline receive Bristol Myers Squibb’s (BMS’s) immunomodulating agent Revlimid (lenalidomide); many participants in the trial are Revlimid primary-refractory. Blenrep recorded sales of $44m in 2023, down significantly from $145m the previous year. GlobalData’s analyst consensus forecast projects a slight uptick in sales, reaching $56m by 2029.
Past Blenrep studies revealed a concern with patients developing eye-related side effects. Unfortunately, these adverse events showed in DREAMM-7 as Grade ≥3 ocular adverse events and occurred in 34% of patients, with 9% of patients discontinuing therapy. Outside of the ocular side effects, high-grade toxicity occurred in both treatment arms including thrombocytopenia in 55% and 35% of the Blenrep and the Darzalex arm, respectively. Other notable toxicities include neutropenia, pneumonia, and anaemia.
The underwhelming sales generated from the BCMA-directed ADC are tied to its history. Blenrep originally received accelerated approval as a fifth-line MM treatment. In the DREAMM-3 confirmatory study, Blenrep as a standalone therapy was unable to demonstrate a marked improvement in PFS compared with the combination of BMS’s Pomalyst (pomalidomide) and dexamethasone. The failure led the FDA to revoke the biologic licence for Blenrep in February 2023; the EMA followed suit several months later, leaving European nation-states the sole discretion as to its marketability in their country. There’s little hope for Blenrep to regain approval in third- or fourth-line MM as the triplet regimen of daratumumab, pomalidomide, and dexamethasone is the SOC. Additionally, J&J’s bispecific antibody Tecvayli (teclistamab) and CAR-T Carvykti (ciltacabtagene autoleucel), as well as BMS’ CAR-T Abecma (idecabtagene vicleucel), are established treatments in the setting. With the interim analysis, GSK can be optimistic about the use of Blenrep potentially becoming a SOC in the second line, far exceeding its current sales projection. The company is also evaluating the ADC in Phase III DREAMM-8 in combination with Polamyst and dexamethasone in the same setting. Additionally, there’s a Phase II study for newly diagnosed stem cell transplant-ineligible MM in combination with the frequently used agents Velcade, Revlimid, and dexamethasone.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData